Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y, Liu P, Cai J, Jing H, Zou L, Huang H, Wu Y, Li W, Zhong L, Jin X, Ye X, Feng R, Zhang H, Zhang L, Lin L, Sun X, Tian Y, Xia Z, Li Z, Huang H, Xia Y, Cai Q.
Zhang Y, et al. Among authors: xia y, xia z.
Cancer Med. 2022 Nov;11(22):4134-4145. doi: 10.1002/cam4.4765. Epub 2022 Apr 19.
Cancer Med. 2022.
PMID: 35438258
Free PMC article.